Use of non-feminizing estrogens as treatment for retinal vascular diseases

Abstract

The invention provides pharmaceutical compositions containing non-feminizing estrogen and methods of using these compositions to prevent or ameliorate retinal vascular diseases.

1. A method for treating a retinal vascular disease selected from the group consisting of a retinal arterial obstructive disease, central retinal vein occlusion, and retinal branch vein occlusion, said method comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising at least one non-feminizing estrogen compound, wherein said non-feminizing estrogen compound is estratriene-3-ol. 
     
     
       2. The method of  claim 1 , wherein said retinal vascular disease is a retinal arterial obstructive disease. 
     
     
       3. The method of  claim 2 , wherein said retinal arterial obstructive disease is selected from the group consisting of central retinal artery obstruction, branch retinal artery obstruction, cilioretinal artery obstruction, ophthalmic artery obstruction, combined central retinal artery and vein obstruction, and cotton-wool spots.